At Huahui Health, the crews explored the company's breakthroughs in developing innovative drugs for major diseases such as hepatitis B and D. The company originated from the National Institute of Biological Sciences, Beijing. In 2012, its scientific founder, Dr. Li Wenhui, led a team that discovered the NTCP cell receptor, essential for hepatitis B and D virus infections. Dr. Li received the highest global award in hepatitis B research and treatment in 2021, as well as the Future Science Prize in 2022. The company's independently developed innovative drug, the monoclonal antibody Libevitug (HH-003), has been granted Breakthrough Therapy Designation by drug regulatory authorities in both China and the United States. It is expected to be approved for market release around the end of 2025.